-
The EU CHMP recommends the approval of Pfizer's 2 JAK inhibitors, Cibinqo (abxitinib) and Xeljanz (tofacitinib)!
Time of Update: 2021-11-04
net) October 19, 2021/Bio Valley BIOON/ --Pfizer (Pfizer) recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive review suggesting that Cibinqo (abrocitinib, Abxitinib, 100mg, 200mg): This drug is a once-daily oral JAK1 inhibitor for the treatment of moderate to severe atopic dermatitis (AD) adult patients who are suitable for systemic treatment .
-
How will this "immature" track be rewritten after the 8-province joint mining?
Time of Update: 2021-11-04
Public information shows that in Shandong Province’s first centralized procurement of high-value medical consumables in December last year, the prices of 5 products of 5 cardiac pacemakers (dual-chamber) companies were reduced by an average of 51.
-
Johnson & Johnson and F-star reach 1.35 billion bispecific antibody therapy cooperation
Time of Update: 2021-11-04
According to the terms of the agreement, F-star will grant Janssen a global exclusive license to use its proprietary Fcab and mAb2 technologies for the research, development and commercialization of up to 5 new bispecific antibody platforms against Janssen's therapeutic targets .
-
Luoxin Pharmaceutical's subsidiary introduced Budesolv®, a solution nasal spray of Budesonide
Time of Update: 2021-11-04
Japan signed the "License Agreement", and reached an agreement on the introduction of Budesolv® (Budesonide solution nasal spray) product, Shandong Luoxin will obtain the product in Greater China (including mainland China, Hong Kong and Macau Special Administrative Region, Taiwan ) The right to exclusive development, production and commercialization .
-
Biosimilar drug market: the expected "fierce fight" is now "calm"
Time of Update: 2021-11-04
"This is because the latecomers of biosimilars continue to launch products, forcing the price of early entrants to drop, and the intensified competition from innovators.
The two companies reached a cooperation agreement on the production of biosimilar drugs in the US market last year .
-
Today, Novartis' SMA gene therapy clinical application in China has been accepted, and the acquisition of the company for US$8.7 billion has been obtained!
Time of Update: 2021-11-04
In May 2019, the therapy was approved for marketing in the United States In terms of clinical efficacy, according to data published earlier by AveXis, in the pivotal clinical trial STR1VE-US, not only 91% of patients with severe type 1 SMA treated with Zolgensma reached the primary endpoint of event-free survival , but 22 patients in nine reached the more stringent "grow" standard .
-
What is the reason behind the high failure rate of 19 pharmaceutical companies that failed to go public?
Time of Update: 2021-11-04
Since the beginning of this year, a total of 10 biopharmaceuticals, pharmaceutical R&D and experimental companies have failed IPOs on the Sci-tech Innovation Board, which is higher than the total of the previous two years (4 in 2019 and 5 in 2020), of which 8 have voluntarily withdrawn .
-
Sun Chunlan emphasized speeding up the research and development of new crown therapeutic drugs during the investigation of the Drug Evaluation Center to provide strong support for the protection of people's health
Time of Update: 2021-11-04
Sun Chunlan, member of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, visited the Drug Evaluation Center of the State Drug Administration on the 19th to learn about the clinical trials and review services of new coronavirus drugs, and held relevant enterprise and Expert seminars to listen to opinions and suggestions on drug research and development work .
-
Beihai Kangcheng approved the clinical trial application of CAN103 new drug for Gaucher's disease
Time of Update: 2021-11-04
Xue Qun, Founder, Chairman and CEO of Beihai Kangcheng, said: “The rapid approval of the CAN103 clinical trial application is a major development for Gaucher patients in China .
-
3 financings in 4 days, domestic cell therapy companies rush to the battlefield of solid tumors passionately
Time of Update: 2021-11-04
However, how to provide patients with TCR-T cell therapy drugs quickly, accurately and effectively is a major pain point that plagues the development of the industry .
In addition to TCR-T, STAR-T, and TIL, NK cell therapy is also involved in solid tumors .
-
Microchip Bio's PPAR full agonist "Sigglita Sodium" was officially approved by NMPA for marketing
Time of Update: 2021-11-04
NASH Potential New DrugNASH Potential New Drug In addition to being used for type 2 diabetes, from the current clinical results, sitaglipta sodium can also significantly reduce aspartate aminotransferase and alanine aminotransferase, which is expected to become non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (NASH/NAFLD).
-
15 products on the market in 2025, one global IND a year, Zai Lab transforms into 3.0, where will it go?
Time of Update: 2021-11-04
"Zai Lab's mid-term goal is to lead the development of new indications in pipeline products or explore new combination therapies based on clinical needs on the one hand, and on the other hand to promote the early stage products of our own research and development and external cooperation to the clinic .
-
The Guangdong "dual channel" catalog is here, and 221 drugs have been included. There are these requirements!
Time of Update: 2021-11-04
The industry predicts that as the "dual channel" policy is successively implemented in various places, the medical insurance negotiation drugs will further achieve a rapid increase in volume, and the market structure inside and outside the hospital may change .
-
Suddenly the shareholders are in trouble!
Time of Update: 2021-11-04
But Acceleron’s two shareholders, activist investor Avoro Capital, which owns 7% of Acceleron’s equity, and Darwin Global Management, a hedge fund that owns 4% of the equity, suddenly went into trouble, believing that Merck acquired the company at a price lower than the billions of dollars worth of Acceleron.
-
New trends in drug procurement
Time of Update: 2021-11-04
" In late June this year, Director Gong Bo of the Medical Service Department of the Shanghai Medical Insurance Bureau made it clear in an interview with News 1+1 that the national centralized procurement of 1-5 batches of 218 chemical drugs involved a total of 220 billion yuan, accounting for all the chemicals in public medical institutions.
-
Newsletter: Wang Cunlin and Guo Tong were successfully selected into the IFPMA ICH M14 expert working group
Time of Update: 2021-11-04
Team Leader: Wang Cunlin, Vice President of Yasheng Pharmaceutical Safety and Pharmacovigilance Expert: Guo Tong, Executive Vice President of ZeroKr Technology In the future, the two experts will also represent the China Association for the Promotion of Pharmaceuticals and the Chinese pharmaceutical industry to speak out on the world stage, strengthen China's right to speak in international organizations, and promote the transformation and implementation of ICH guidelines in China .
-
Will the PROTAC, which Hengrui is working hard to develop, become the next-generation drug king?
Time of Update: 2021-11-03
Third, it only takes a small amount to be effective, can be used repeatedly, and is highly targeted " In December 2020, Arvinas, a pioneer in PROTAC technology, disclosed the results of clinical trials of two related products: One of the products under development is called ARV-471, which is an oral protein degrading agent that targets the estrogen receptor (ER) and can be used to treat breast cancer .
-
The fifth batch of centralized procurement, the latest landing situation announced
Time of Update: 2021-11-03
HubeiHubei On October 22, the Hubei Province Pharmaceutical Price and Bidding Purchasing Management Service Network issued the "On the Implementation of the Fifth Batch of National-Organized Drug Centralized Procurement and Chongqing, Eqiong, Dianqing, Ningxia New Xinjiang Corps Common Drug Union Procurement (Hubei) non-selected varieties "Notice on Information Declaration and Net Price Adjustment" .
-
Nobel Prize Technology RNA Interference: A Decade of Hot Spots
Time of Update: 2021-11-03
Although there are many large-scale companies in the field of RNAi technology, the industry concentration is not high, and new and cutting-edge companies still have the opportunity to stand out by virtue of their differentiated advantages in this field .
-
H1 Global Top 5 Diabetes Pharmaceutical Companies Revenue and Main Products Inventory in 2021
Time of Update: 2021-11-03
According to the interim financial statements, we have sorted out the multinational pharmaceutical companies with a diabetes business revenue of over US$1 billion in the first half of the year and their main products, as shown in the figure below: Data source: Mid-term annual reports of various companies The five major pharmaceutical companies in the first half of 2021 had 24 diabetes drugs with a sales volume of over 100 million U.
